P2.02-005 13 Cases of Molecular Features Analysis in Pulmonary Mucoepidermoid Carcinoma

C. Xu,W. Wang,W. Zhuang,Zhengbo Song,Y. Chen,Gang Chen,M. Fang,T. Lv,You Song
DOI: https://doi.org/10.1016/j.jtho.2017.09.1182
IF: 20.121
2017-01-01
Journal of Thoracic Oncology
Abstract:The cases of pulmonary mucoepidermoid carcinoma (PMEC) are extremely rare. There is only limited data on treatment outcome for chemotherapy in PMEC, and less so for targeted therapy such as targeted therapy with icotinib. The aim of this study is to investigate the molecular characteristics of pulmonary mucoepidermoid carcinoma (PMEC). From July 2013 to December 2016, 13 PMEC patients received treatment. All the patients were diagnosed by pathology. We retrospectively reviewed the clinical data and genetic state. EGFR mutation rate was 15.38% (2/13), and 2 cases were both L861Q point mutations, the relationship between EGFR gene status and gender (P=1.000), age (P=1.000), smoking (P=0.848) and stage (P=1.000) were no significant, respectively; the positive rate of MAML2 fusion gene was 45.45% (5/11). The relationship between MAML2 fusion gene status and gender (P=0.521), age (P=0.521), smoking (P=1.000) and stage (P=0.924) were no significant, respectively. The most common form change of pulmonary mucoepidermoid carcinoma is EGFR gene L861Q point mutation, MALM2 fusion genes exist in the EGFR gene wild type patients. Icotinib treatment may benefit from patients with EGFR L861Q point mutations and MALM2 fusion gene.
What problem does this paper attempt to address?